FDA Approves First Oral PCSK9 Inhibitor

• by Kathryn Wighton

• July 16, 2026

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

• by Kathryn Wighton

• July 17, 2026

• 2 min

Frailty may not limit semaglutide benefits

Patients with greater frailty showed larger improvements in health-related quality of life, while cardiovascular treatment effects did not differ significantly across frailty categories.

• by Andrea Surnit

• October 16, 2026

• 5 min

TOFA may drive weight loss without reducing food intake

The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.

• by Andrea Surnit

• August 27, 2026

• 4 min